High cost of Xtandi, treatment for prostate cancer, could be solved using “March-In” rights

Federal government is urged to take action on drug prices for key treatment for prostate cancer

It's been one year since four patients living with prostate cancer asked the federal government to use its "March-In" rights to bring down the costs of Xtandi. We're still waiting for an answer. PIRG followed up with this request.

PIRG writes on behalf of the public interest to address high drug prices.

Take Action

Topics
Authors

Patricia Kelmar

Senior Director, Health Care Campaigns, PIRG

Patricia directs the health care campaign work for U.S. PIRG and provides support to our state offices for state-based health initiatives. Her prior roles include senior policy advisor at NJ Health Care Quality Institute, associate state director at AARP New Jersey and consumer advocate at NJPIRG. She was appointed to the Ground Ambulance and Patient Billing Advisory Committee in 2022 and works with patient advocates across the U.S. Patricia enjoys walking along the Potomac River and sharing her love of books with friends and family around the world.